Research ArticleClinical Studies

Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer

HIDEAKI MIYAKE, YUTO MATSUSHITA, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, TOSHIKI ITO, TAKAYUKI SUGIYAMA and ATSUSHI OTSUKA
Anticancer Research March 2019, 39 (3) 1391-1396; DOI: https://doi.org/10.21873/anticanres.13253

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Overall survival from diagnosis in patients with metastatic castration-sensitive prostate cancer who received primary androgen deprivation therapy and subsequently developed castration-resistant prostate cancer according to the time to castration resistance (TTCR).

  • Figure 2.
    Figure 2.

    Overall survival from the development of castration-resistant prostate cancer (CRPC) in patients with metastatic castration-sensitive prostate cancer who received primary androgen deprivation therapy according to the time to castration resistance (TTCR).

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer
HIDEAKI MIYAKE, YUTO MATSUSHITA, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, TOSHIKI ITO, TAKAYUKI SUGIYAMA, ATSUSHI OTSUKA
Anticancer Research Mar 2019, 39 (3) 1391-1396; DOI: 10.21873/anticanres.13253
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords